1044871-58-0

Basic information

• Product Name: propylcarbamic acid-2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl ester
• Synonyms: propylcarbamic acid-2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl ester
• CAS NO: 1044871-58-0
• Molecular Weight: 455.511
• Mol File: 1044871-58-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: propylcarbamic acid-2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: propylcarbamic acid-2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl ester(1044871-58-0)
• EPA Substance Registry System: propylcarbamic acid-2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)ethyl ester(1044871-58-0)

Safety Data

• Hazardous Substances Data: 1044871-58-0(Hazardous Substances Data)

Upstream product

• 1039948-89-4 4-(2-hydroxy ethoxy)-3,5-dimethyl benzaldehyde 
• 10272-07-8 3.5-dimethoxyaniline 
• 40891-33-6 3,5-dimethoxyaniline hydrochloride 
• 110-78-1 Propyl isocyanate 
• 1044870-92-9 2-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)-2,6-dimethylphenoxy)acetic acid 
• 2233-18-3 4-hydroxy-3,5-dimethylbenzaldehyde 
• 21544-81-0 4,6-dimethoxyindoline-2,3-dione 
• 1044870-39-4 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxy-3,4-dihydroquinazoline-4-one 
• 21577-57-1 2-amino-4,6-dimethoxybenzoic acid 
• 63920-73-0 2-amino-4,6-dimethoxybenzamide 

Relevant articles and documents

Used for the prevention and treatment of cardiovascular diseases

The invention relates to compounds that can be used for adjusting the expression of apolipoprotein A-I (ApoA-I) and usage of the compounds in treating and preventing cardiovascular diseases and related diseases, including the disorder related to cholesterol or lipids such as atherosclerosis.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotei? A-I (ApoA-l), and their use for the treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.